Increased urocortin 3 levels are associated with the risk of having type 2 diabetes mellitus.

Autor: Alarslan P; Division of Endocrinology and Metabolism, Department of Internal Medicine, Izmir Bozyaka Training and Research Hospital, Izmir, Turkey., Unal Kocabas G; Division of Endocrinology and Metabolism, Department of Internal Medicine, Izmir Bozyaka Training and Research Hospital, Izmir, Turkey., Demir I; Department of Internal Medicine, Izmir Bozyaka Training and Research Hospital, Izmir, Turkey., Guler A; Department of Family Physician, Izmir Bozyaka Training and Research Hospital, Izmir, Turkey., Bozkaya G; Department of Clinical Biochemistry, Izmir Bozyaka Training and Research Hospital, Izmir, Turkey., Aslanipour B; Department of Biotechnology, Graduate School of Natural and Applied Sciences, Ege University, Izmir, Turkey., Calan M; Division of Endocrinology and Metabolism, Department of Internal Medicine, Izmir Bozyaka Training and Research Hospital, Izmir, Turkey.
Jazyk: angličtina
Zdroj: Journal of diabetes [J Diabetes] 2020 Jun; Vol. 12 (6), pp. 474-482. Date of Electronic Publication: 2020 Jan 13.
DOI: 10.1111/1753-0407.13020
Abstrakt: Background: Urocortin 3 (UCN3) is a peptide hormone playing a pivotal role in glucose and lipid metabolisms. However, its clinical implications remain unclear. Our aims were to investigate the altered levels of UCN3 in newly diagnosed type 2 diabetes mellitus (nT2DM) patients in comparison to subjects with normal glucose tolerance (NGT) and to determine the presence of any possible link between UCN3 levels and metabolic parameters.
Methods: Eighty nT2DM and 80 age-, body mass index (BMI)-, and gender-matched NGT subjects were enrolled into this case-control study. The circulating UCN3 levels were measured using the enzyme-linked immunoabsorbent assay (ELISA). Metabolic parameters of enrolled subjects were also determined. A standard 75-g 2-hour oral glucose tolerance test was used for diagnosis of type 2 diabetes mellitus (T2DM).
Results: UCN3 levels were higher in subjects with nT2DM than in controls (115.64 ± 39.26 vs 86.16 ± 22.81 pg/mL, P < .001). UCN3 levels were increased in subjects with metabolic syndrome compared to subjects without metabolic syndrome in both nT2DM and NGT groups. UCN3 levels showed a positive correlation with BMI in both groups. Moreover, UCN3 levels were positively and independently associated with insulin, fasting blood glucose, insulin resistance, 2-hour plasma glucose, glycosylated hemoglobin, and triglycerides, whereas UCN3 levels were negatively and independently associated with high-density lipoprotein cholesterol. According to logistic regression analysis, increased risk of T2DM and metabolic syndrome were parallel with the highest elevated levels of UCN3.
Conclusions: Increased levels of UCN3 are associated with unfavorable metabolic profiles in T2DM, indicating a potential role of UCN3 in glucose and lipid metabolisms in T2DM.
(© 2020 Ruijin Hospital, Shanghai Jiaotong University School of Medicine and John Wiley & Sons Australia, Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje